Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
about
Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentratesTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXParallel use of by-passing agents in haemophilia with inhibitors: a critical review.Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceSequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent.Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors.How I treat inhibitors in haemophilia.How we treat: Considerations for physiotherapy in the patient with haemophilia and inhibitors undergoing elective orthopaedic surgery.Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
P2860
Q27026389-4105B506-02C4-47BF-8D0E-65B46E84F4D5Q33608230-A639AD46-2929-4054-8008-17D379501DF6Q37927122-DA5003CA-51C7-4093-B559-8013D3DA86AFQ38044492-0E63457B-BC41-4B73-B116-90F4CA14C1FFQ38101041-52BD6569-07A3-44EA-916A-1F09F475B24EQ38182105-4F285651-FF11-4613-AAFD-CEFD579E54F0Q39216258-25A44436-81C1-4035-AA4B-13F85DE998F5Q44211358-B5F97BA8-D918-48DA-8BB4-578CC87BFFC5Q45220897-61DC194A-F8BC-4A31-BA77-D192EFF69B9DQ45838031-832941FF-004A-407C-8BA3-2EE2E3422324Q45856751-9A47AC4F-B9CF-44D8-887A-9CB944F9F435Q45862378-7261849E-9419-4488-B570-D75C45D7F71DQ45862969-B21B565A-997F-4E3D-A8BF-E1C282F2A94CQ45865165-D7AA7097-0B93-48D0-B16A-FD79C07A0494Q45869629-0B764578-1687-4FE5-A176-5920EAFAA0CAQ45879927-212C2DB1-477C-416D-A100-CD091584F3BEQ45881465-4D2B9CEB-D36A-422D-A04A-EEC8C3BF6D55Q45886119-7AC71344-15C9-4901-93C1-37AB5B08F4FAQ45887437-84C88E7C-0A34-4414-A9A8-7C80F550DE12Q45887517-14CD874C-228F-4AB2-9E98-4D97E1FB63FDQ45888065-104DB625-E4CC-43AA-8C1F-33D02BBEC0D1Q50924464-3909FD10-3988-4063-BAC1-885F75F2A82A
P2860
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sequential combined bypassing ...... th haemophilia and inhibitors.
@en
Sequential combined bypassing ...... th haemophilia and inhibitors.
@nl
type
label
Sequential combined bypassing ...... th haemophilia and inhibitors.
@en
Sequential combined bypassing ...... th haemophilia and inhibitors.
@nl
prefLabel
Sequential combined bypassing ...... th haemophilia and inhibitors.
@en
Sequential combined bypassing ...... th haemophilia and inhibitors.
@nl
P2093
P2860
P1433
P1476
Sequential combined bypassing ...... th haemophilia and inhibitors.
@en
P2093
A Gringeri
A Karafoulidou
European Haemophilia Treatment Standardisation Board (EHTSB)
M F López-Fernández
R Klamroth
P2860
P304
P356
10.1111/J.1365-2516.2010.02467.X
P577
2011-02-15T00:00:00Z